THE PROGNOSIS, PREOPERATIVE S-1 TREATMENT RESPONSE, AND CLINICOPATHOLOGICAL CHARACTERISTICS ARE ASSOCIATED WITH TERTIARY LYMPHOID FORMATIONS IN TONGUE CANCER
Main Article Content
Keywords
Tertiary lymphoid structure, squamous cell carcinoma, S-1, preoperative chemotherapy
Abstract
Objective: The purpose of this study was to assess the connection between TLSs and prognosis in tongue squamous cell carcinoma (TSCC) patients following preoperative S-1 treatment.
Study Design: Clinical Randomized trial
Place and Duration: Department of Oral Pathology, Baqai Medical University, Karachi. Nov 2022-Aug 2023.
Methods: Total 165 TSCC patients were presented in this study. Following informed written consent, comprehensive demographics were recorded. 90 patients received S-1 chemotherapy in group I and 75 patients were included in group II without S-1 treatment. We looked into TLS occurrence in both resected and preoperative biopsy specimens. All of the data were analysed using SPSS 23.0.
Results: Thirty-two (18.2%) resected specimens and twenty-seven (16.4%) biopsy specimens had TLSs. TLSs were linked to lymphatic invasion positive and instances that were clinicopathologically progressed. TLSs were absent from every instance with pStage 0, or benign cancer. TLSs were substantially more prevalent in preoperative S-1 chemotherapy instances in patients treated with S-1 for longer than 21 days, as well as in patients with treatment effects, stage (1,2). When compared with preoperative S-1 treatment, TLSs may be a prognostic factor, however they may not be one by themselves.
Conclusion: When evaluating the indication for preoperative S-1 treatment, the existence of TLSs was proposed as a factor indicating a favorable prognosis. Patients with TLSs who have TSCC may have a better prognosis due to the synergistic effect of S-1, which activates antitumor immunity.
References
2. Rakaee M, Kilvaer TK, Jamaly S, Berg T, Paulsen EE, Berglund M, et al. Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer. Br J Cancer. 2021;124:1680–9.
3. Almangush A, Pirinen M, Youssef O, Makitie AA, Leivo I. Risk stratification in oral squamous cell carcinoma using staging of the eighth American Joint Committee on Cancer: systematic review and meta-analysis. Head Neck. 2020;42:3002–17.
4. Gago da Graca, C., van Baarsen, L. G. M. & Mebius, R. E. Tertiary lymphoid structures: diversity in their development, composition, and role. J. Immunol. 206, 273–281 (2021).
5. Sato, Y. & Yanagita, M. Immunology of the ageing kidney. Nat. Rev. Nephrol. 15, 625–640 (2019).
6. Ruddle, N. H. Lymphatic vessels and tertiary lymphoid organs. J. Clin. Invest. 124, 953–959 (2014).
7. Pitzalis C, Jones GW, Bombardieri M, Jones SA. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat Rev Immunol. 2014;14(7):447–462.
8. Sautes-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19(6):307–325.
9. Martinet L. High endothelial venules (HEVs) in human melanoma lesions: major gateways for tumor-infiltrating lymphocytes. Oncoimmunology. 2012;1(6):829–839.
10. Zhang WH, Wang WQ, Han X, Gao HL, Xu SS, Li S, et al. Infiltrating pattern and prognostic value of tertiary lymphoid structures in resected non-functional pancreatic neuroendocrine tumors. J Immunother Cancer. 2020;8:e001188.
11. Yamakoshi Y, Tanaka H, Sakimura C, Deguchi S, Mori T, Tamura T, et al. Immunological potential of tertiary lymphoid structures surrounding the primary tumor in gastric cancer. Int J Oncol. 2020;57:171–82.
12. Sautes-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19:307–25.
13. Adachi, Y. et al. Distinct germinal center selection at local sites shapes memory B cell response to viral escape. J. Exp. Med. 212, 1709–1723 (2015).
14. Cippa, P. E. et al. A late B lymphocyte action in dysfunctional tissue repair following kidney injury and transplantation. Nat. Commun. 10, 1157 (2019).
15. Singh, P. et al. Lymphoid neogenesis and immune infiltration in aged liver. Hepatology 47, 1680–1690 (2008).
16. Van Dijk N. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med. 2020;12.
17. Cottrell TR. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol. 2018;29(8):1853–1860.
18. Joshi NS, Akama-Garren EH, Lu Y, Lee DY, Chang GP, Li A, DuPage M, Tammela T, Kerper NR, Farago AF, et al. Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. Immunity. 2015;43(3):579–90
19. Yamaguchi K, Ito M, Ohmura H, Hanamura F, Nakano M, Tsuchihashi K, Nagai S, Ariyama H, Kusaba H, Yamamoto H, et al. Helper T cell-dominant tertiary lymphoid structures are associated with disease relapse of advanced colorectal cancer. Oncoimmunology. 2020;9(1):1724763.
20. Barros LRC, Souza-Santos PT, Pretti MAM, Vieira GF, Bragatte MAS, Mendes MFA, De Freitas MV, Scherer NM, De Oliveira IM, Rapozo DCM, et al. High infltration of B cells in tertiary lymphoid structures, TCR oligoclonality, and neoantigens are part of esophageal squamous cell carcinoma microenvironment. J Leukoc Biol. 2020;108(4):1307–18.
21. Silina K, Soltermann A, Attar FM, Casanova R, Uckeley ZM, Thut H, Wandres M, Isajevs S, Cheng P, Curioni-Fontecedro A, et al. Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. Cancer Res. 2018;78(5):1308–20
22. Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, SadeFeldman M, Blando J, Han G, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549–55.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Muhammad Masood Ahmad
PhD Biochemistry Scholar, Government College University Faisalabad
Nimra Noreen
Lecturer, Department of Oral Pathology, Baqai Medical University, Karachi
Noor Ul Ain Malik
Department of Biosciences, COMSATS University, Islamabad, Pakistan
Ayesha Mehboob
Rawal Institute of Health Sciences, Lethrar Road, Islamabad
Khawar Malik
Pakistan Institute of Medical Sciences, Islamabad
Hasnain Zafar
M.Phil Zoology, Institute of Zoology, Bahauddin Zakariya University, Multan, Pakistan